149 related articles for article (PubMed ID: 2044726)
1. Cardiotoxicity of epirubicin and doxorubicin: a double-blind randomized study.
Lahtinen R; Kuikka J; Nousiainen T; Uusitupa M; Länsimies E
Eur J Haematol; 1991 May; 46(5):301-5. PubMed ID: 2044726
[TBL] [Abstract][Full Text] [Related]
2. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients.
Nousiainen T; Jantunen E; Vanninen E; Hartikainen J
Br J Cancer; 2002 Jun; 86(11):1697-700. PubMed ID: 12087452
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of effectiveness of adriamycin and epirubicin administered in the CHOP protocol to patients with malignant non-hodgkin's lymphoma].
Rolski J; Koralewski P; Pawlicki M
Wiad Lek; 1993 May; 46(9-10):356-9. PubMed ID: 8236992
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy including epirubicin for the management of non-Hodgkin's lymphoma.
Al-Ismail SA; Whittaker JA; Gough J
Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1379-84. PubMed ID: 3315698
[TBL] [Abstract][Full Text] [Related]
5. Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults.
Avilés A; Arévila N; Díaz Maqueo JC; Gómez T; García R; Nambo MJ
Leuk Lymphoma; 1993 Oct; 11(3-4):275-9. PubMed ID: 8260898
[TBL] [Abstract][Full Text] [Related]
6. [Late cardiotoxicity in patients with malignant lymphoma treated with doxorubicin chemotherapy].
Elbl L; Vásová I; Navrátil M; Tomásková I; Jedlicka F; Chaloupka V; Vorlícek J
Vnitr Lek; 2006 Apr; 52(4):328-38. PubMed ID: 16755989
[TBL] [Abstract][Full Text] [Related]
7. Acute myocardial infarction in man treated with epirubicin for non-Hodgkin lymphoma.
Aydiner A; Buğra Z; Topuz E; Meriç M
Am J Clin Oncol; 1995 Oct; 18(5):444-8. PubMed ID: 7572766
[TBL] [Abstract][Full Text] [Related]
8. Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy.
Kang Y; Xu X; Cheng L; Li L; Sun M; Chen H; Pan C; Shu X
Eur J Heart Fail; 2014 Mar; 16(3):300-8. PubMed ID: 24464946
[TBL] [Abstract][Full Text] [Related]
9. Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial.
Xue K; Gu JJ; Zhang Q; Liu X; Wang J; Li XQ; Luo J; Hernandez-Ilizaliturri FJ; Fernandez SF; Czuczman MS; Cao J; Hong X; Guo Y
Oncotarget; 2016 May; 7(22):32519-31. PubMed ID: 27081036
[TBL] [Abstract][Full Text] [Related]
10. Effects of Doxorubicin, Epirubicin, and Liposomal Doxorubicin (Anthracycline) on cardiac function in patients with osteosarcoma and their influencing factors.
Ding S; Xiong S; Wang X; Zhang C; Chen S; Sun M; Wu C; Zhang X; Wang M; Wang J; Shang X
Clin Transl Oncol; 2024 Jun; 26(6):1459-1466. PubMed ID: 38329609
[TBL] [Abstract][Full Text] [Related]
11. Treatment of aggressive non-Hodgkin's lymphoma with dose-intensified epirubicin in combination of cyclophosphamide, vincristine, and prednisone (CEOP-100): a phase II study.
Basaran M; Bavbek ES; Sakar B; Eralp Y; Alici S; Tas F; Yaman F; Dogan O O; Camlica H; Onat H
Am J Clin Oncol; 2001 Dec; 24(6):570-5. PubMed ID: 11801756
[TBL] [Abstract][Full Text] [Related]
12. Comparison of epirubicin and doxorubicin cardiotoxicity in children and adolescents treated within the German Cooperative Soft Tissue Sarcoma Study (CWS).
Stöhr W; Paulides M; Brecht I; Kremers A; Treuner J; Langer T; Beck JD;
J Cancer Res Clin Oncol; 2006 Jan; 132(1):35-40. PubMed ID: 16205946
[TBL] [Abstract][Full Text] [Related]
13. [Pirarubicin-induced myocardial damage in elderly patients with non-Hodgkin's lymphoma].
Niitsu N; Yamazaki J; Nakayama M; Umeda M
Nihon Ronen Igakkai Zasshi; 1998 May; 35(5):358-62. PubMed ID: 9735010
[TBL] [Abstract][Full Text] [Related]
14. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
Venturini M; Michelotti A; Del Mastro L; Gallo L; Carnino F; Garrone O; Tibaldi C; Molea N; Bellina RC; Pronzato P; Cyrus P; Vinke J; Testore F; Guelfi M; Lionetto R; Bruzzi P; Conte PF; Rosso R
J Clin Oncol; 1996 Dec; 14(12):3112-20. PubMed ID: 8955656
[TBL] [Abstract][Full Text] [Related]
15. Cyclophosphamide, epirubicin, vincristine, and prednisone (CEOP) in the treatment of advanced stage non-Hodgkin's lymphomas with poor histology.
Comella P; Abate G; Fiore M; Di Finizio G; Zarrilli D
J Chemother; 1989 Jul; 1(4 Suppl):1257-8. PubMed ID: 16312856
[No Abstract] [Full Text] [Related]
16. ProMECE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma: long term results of a multicenter study of the Italian Lymphoma Study Group (GISL).
Silingardi V; Federico M; Cavanna L; Avanzini P; Gobbi PG; Lombardo M; Carotenuto M; Frassoldati A; Pieresca C; Vallisa D
Leuk Lymphoma; 1995 Apr; 17(3-4):313-20. PubMed ID: 8580801
[TBL] [Abstract][Full Text] [Related]
17. Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: evolution of the diastolic and systolic parameters studied by radionuclide angiography.
Cottin Y; Touzery C; Dalloz F; Coudert B; Toubeau M; Riedinger A; Louis P; Wolf JE; Brunotte F
Clin Cardiol; 1998 Sep; 21(9):665-70. PubMed ID: 9755384
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer.
Ghasemi K; Vaseghi G; Mansourian M
J Oncol Pharm Pract; 2021 Mar; 27(2):414-427. PubMed ID: 33081570
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi.
Merli F; Luminari S; Rossi G; Mammi C; Marcheselli L; Tucci A; Ilariucci F; Chiappella A; Musso M; Di Rocco A; Stelitano C; Alvarez I; Baldini L; Mazza P; Salvi F; Arcari A; Fragasso A; Gobbi PG; Liberati AM; Federico M
Leuk Lymphoma; 2012 Apr; 53(4):581-8. PubMed ID: 21895543
[TBL] [Abstract][Full Text] [Related]
20. Treatment of diffuse large B-cell lymphoma in elderly patients: Replacing doxorubicin with either epirubicin or etoposide (VP-16).
Prusila REI; Peroja P; Jantunen E; Turpeenniemi-Hujanen T; Kuittinen O
Hematol Oncol; 2019 Apr; 37(2):136-142. PubMed ID: 30589950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]